Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-26 EDT 5-day change 1st Jan Change
122.4 USD -11.01% Intraday chart for Moderna, Inc. -8.12% +23.13%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Health Care Down as Moderna Slides -- Health Care Roundup DJ
Equities Mostly Rise as Markets Weigh New-Home Sales Data MT
Equities Rise as Markets Weigh New-Home Sales Data MT
US Equities Markets Close Higher Wednesday as Markets Review New Home Sales Data MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Moderna Shares Fall as RSV Shot Efficacy Lags Behind Rivals' Vaccines, CDC Data Shows MT
CDC advisers narrow age recommendation for RSV shots in US RE
Sector Update: Health Care MT
US CDC Advisers Recommend RSV Vaccine For Adults Aged 60 Years Of Age And Above RE
Moderna RSV Shot Efficacy Lower Than Rivals' Vaccines, CDC Data Shows MT
Moderna RSV Shot Efficacy Lower Than Rivals', CDC Data Shows; Shares Down 9.5% MT
Equity Markets Mixed Intraday as Traders Parse New-Home Sales Data MT
Sector Update: Health Care Stocks Lower in Afternoon Trading MT
US Equity Indexes Gyrate Before Micron Technology Results; New-Home Sales Slump MT
Moderna Says mRESVIA RSV Vaccine Showed 50% Efficacy After 18 Months MT
Argus Raises Moderna's Price Target to $150 From $115 MT
FDA asks COVID vaccine makers to target KP.2 strain with updated shots RE
Moderna: successful trial for new Covid vaccine CF
Moderna's New COVID-19 Vaccine Meets Primary Efficacy Endpoint MT
Moderna Says its Phase 3 Trial of mRNA-1283 Meets Primary Vaccine Efficacy Endpoint Against COVID-19 MT
Moderna's next-gen COVID vaccine shows non-inferiority to current shot RE
Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283 CI
Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says MT
JPMorgan Raises Price Target on Moderna to $96 From $85 MT
Oppenheimer Raises Price Target on Moderna to $179 From $163 MT
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
122.4 USD
Average target price
145.9 USD
Spread / Average Target
+19.11%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Sector Update: Health Care Stocks Hanging on for Monday Gains